IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. Its services include medical treatments, regenerative medicine, physical medicine, physical therapy, spinal decompression and chiropractic manipulation. The company was founded by Matthew C. Wallis, Jason William Brame and Jeffrey S. Ervin in August 2000 and is headquartered in Franklin, TN.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
Unknown
1
100.0%
暂无批准数据
- Ignite Proteomics and Vanderbilt University Medical Center have launched a one-year research collaboration to characterize protein-signaling pathways that help breast tumor cells evade immune system detection. - The partnership will utilize Ignite's reverse-phase protein array platform to analyze up to 80 tumor specimens, profiling priority targets including MHC-I/II, PD-L1, AKT/mTOR, and EGFR/HER2 signaling pathways. - The collaboration aims to identify actionable biomarkers that could refine immunotherapy strategies, addressing the current limitation where objective response rates to immune checkpoint blockade remain below 40 percent. - Initial data packages are expected within two months of sample receipt, with Ignite receiving first rights to negotiate exclusive licensing for any jointly developed intellectual property.
• Ignite Proteomics launches a novel precision oncology assay using Reverse Phase Protein Array (RPPA) technology for breast cancer treatment decisions. • A case study demonstrated a complete response in a metastatic triple-negative breast cancer patient treated with trastuzumab deruxtecan (T-DXd) after RPPA identified HER2 expression. • The RPPA assay uniquely measures both the expression and activated protein drug target levels in breast tumors, improving targeted therapy effectiveness. • This clinically validated assay represents a significant advancement in personalized oncology care, potentially impacting patient outcomes.
